Could a pill ease long COVID fatigue? new trial hopes to find out
NCT ID NCT06597396
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2a trial tests whether the drug abrocitinib can reduce severe fatigue in adults with Long COVID. About 46 people who were never hospitalized for COVID but now have long-term fatigue will take either 50 mg, 100 mg of abrocitinib, or a placebo daily for 12 weeks. Researchers will measure changes in fatigue and overall health using standard questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abrocitinib (a drug taken by mouth)
What this could lead to
If it works, this could point toward a treatment for severe fatigue in people with Long COVID.
What could go wrong
This is a small, early-phase trial with only 46 people. The drug may not improve fatigue more than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATIGUE SYMPTOM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States